Doxorubicin pathways

Caroline F. Thorn, Connie Oshiro, Sharon Marsh, +4

Pharmacogenetics and Genomics

Author InformationLiterary TheoryHumanitiesLiterary HistoryLiterary Criticism +4

Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions

Wen‐Hung Chung, Shiou‐Hwa Jee, WenChieh Chen, +15

Pharmacogenetics and Genomics

A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

Christine Lonjou, Nicolas Borot, Peggy Sekula, +11

Pharmacogenetics and Genomics

Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability

Andrew D. Johnson, Audrey C. Papp, Deanna L. Kroetz, +1

Pharmacogenetics and Genomics

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

Marja K. Pasanen, Mikko Neuvonen, Pertti J. Neuvonen, +1

Pharmacogenetics and Genomics

Very important pharmacogene summary

Laura M. Hodges, Svetlana Markova, Leslie W. Chinn, +4

Pharmacogenetics and Genomics

Author InformationLaura M.Performance StudiesPharmacological StudyImportant Pharmacogene Summary +8

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

Margalida Rotger, Sara Colombo, Hansjakob Furrer, +7

Pharmacogenetics and Genomics

SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid

Aleksi Tornio, Juha Vakkilainen, Mikko Neuvonen, +3

Pharmacogenetics and Genomics

Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population

Wichittra Tassaneeyakul, Thawinee Jantararoungtong, Pei‐Jer Chen, +10

Pharmacogenetics and Genomics

CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure

Johanna Sistonen, Antti Sajantila, Óscar Lao, +3

Pharmacogenetics and Genomics